Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090779 · ClinicalTrials.gov registry record · Phase 2
Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV
A Phase 2 study, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- Terminated
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00090779 is a Phase 2 study that was terminated before completion, run by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. The registered enrollment target is 130 participants.
The verdict
NCT00090779, a Phase 2 study, was terminated before completion, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drugs when they are first infected.
Interventions
- DRUG Lopinavir/Ritonavir
- DRUG Emtricitabine/ tenofovir disoproxil fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090779
The ClinicalTrials.gov registry entry for NCT00090779 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lopinavir/Ritonavir is the first listed.
NCT00090779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090779 about?
NCT00090779 is a clinical study titled "Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV". Although some doctors favor starting anti-HIV treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in long-term benefits or harm. The purpose of this study is to learn whether or not people should take anti-HIV drug...
What is the current status of trial NCT00090779?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2005-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00090779?
The interventions under investigation include: Lopinavir/Ritonavir (DRUG), Emtricitabine/ tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT00090779?
This trial is sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.